{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:56:36Z","timestamp":1784210196779,"version":"3.55.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>In addition to the clear cardiovascular benefit, there has been renewed interest in the potential of statins in the prevention of cognitive impairment and dementia in older adults. However, whether ongoing statin use can delay cognitive decline or dementia progression in those with established Alzheimer dementia, is unclear.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Methods<\/jats:title><jats:p>Using data from NILVAD, we analysed the association between ongoing statin use and cognitive decline (Alzheimer Disease Assessment Scale-Cognitive Subsection [ADAS-Cog])\/dementia progression (Clinical Dementia Rating Scale [CDR-Sb]\/Disability Assessment for Dementia [DAD]) over 18 months in older adults with mild-moderate AD. Additionally, we assessed the association between ongoing statin use and adverse events in mild-moderate AD.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Results<\/jats:title><jats:p>Over one-third (34.9%) of 510 older adults with mild-moderate AD (aged: 72.9 years; 61.9% female) used a statin for the 18-month study duration. Statin use was not associated with the rate of cognitive decline (\u03b2: -0.67; 95% CI: -1.71, 0.36, p = 0.20) or dementia progression (\u03b2: -0.34; 95% CI -0.71, 0.02; p = 0.07 for CDR-Sb\/ \u03b2: -2.00; -5.70, 1.70; p = 0.29 for DAD). Further, ongoing statin use was not associated with adverse events, serious adverse events, unscheduled GP visits, or unscheduled hospitalisation.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Conclusion<\/jats:title><jats:p>Ongoing statin use was not associated with cognitive decline or dementia progression in mild-moderate AD. Similarly, use was not associated with adverse events including abnormal liver function tests or falls. Whilst safe in those with AD, the current results suggest ongoing statin use does not delay cognitive decline or clinical progression in established AD.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0285529","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:28:59Z","timestamp":1683826139000},"page":"e0285529","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["What is the impact of ongoing statin use on cognitive decline and dementia progression in older adults with mild-moderate Alzheimer disease?"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3866-8236","authenticated-orcid":true,"given":"Claire","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1356-510X","authenticated-orcid":true,"given":"Adam H.","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Kennelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the NILVAD study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"issue":"1","key":"pone.0285529.ref001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey.","volume":"2","author":"JA Salami","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"9346","key":"pone.0285529.ref002","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"J Shepherd","year":"2002","journal-title":"Lancet"},{"issue":"9326","key":"pone.0285529.ref003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"pone.0285529.ref004","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacc.2007.06.063","article-title":"Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis","volume":"51","author":"J Afilalo","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"pone.0285529.ref005","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1046\/j.1532-5415.2002.50367.x","article-title":"Mixed dementia: epidemiology, diagnosis, and treatment.","volume":"50","author":"D Zekry","year":"2002","journal-title":"J Am Geriatr Soc."},{"issue":"3","key":"pone.0285529.ref006","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jgs.16342","article-title":"Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta-Analysis.","volume":"68","author":"KAS Davis","year":"2020","journal-title":"J Am Geriatr Soc."},{"issue":"1","key":"pone.0285529.ref007","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jacl.2020.10.007","article-title":"Association between statin use and cognitive function: A systematic review of randomized clinical trials and observational studies.","volume":"15","author":"A Adhikari","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"2","key":"pone.0285529.ref008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11886-014-0559-3","article-title":"Statins and cognitive function: an updated review.","volume":"17","author":"S Chatterjee","year":"2015","journal-title":"Curr Cardiol Rep."},{"issue":"9242","key":"pone.0285529.ref009","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"H Jick","year":"2000","journal-title":"Lancet"},{"key":"pone.0285529.ref010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1741-7015-5-20","article-title":"Simvastatin is associated with a reduced incidence of dementia and Parkinson\u2019s disease.","volume":"5","author":"B Wolozin","year":"2007","journal-title":"BMC Med."},{"issue":"1","key":"pone.0285529.ref011","doi-asserted-by":"crossref","first-page":"e12108","DOI":"10.1002\/trc2.12108","article-title":"Statin therapy and risk of Alzheimer\u2019s and age-related neurodegenerative diseases.","volume":"6","author":"G Torrandell-Haro","year":"2020","journal-title":"Alzheimers Dement (N Y)."},{"issue":"10","key":"pone.0285529.ref012","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1073\/pnas.101123198","article-title":"A fluid connection: cholesterol and Abeta","volume":"98","author":"B. Wolozin","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0285529.ref013","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003160","article-title":"Statins for the prevention of Alzheimer\u2019s disease and dementia.","author":"HD Scott","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"pone.0285529.ref014","article-title":"Statins for the prevention of dementia.","author":"B McGuinness","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"pone.0285529.ref015","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"HH Feldman","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"pone.0285529.ref016","first-page":"1391","article-title":"The efficacy of statins in the treatment of Alzheimer\u2019s disease: a meta-analysis of randomized controlled trial.","volume":"41","author":"K Xuan","journal-title":"Neurol Sci. 2020 Jun"},{"key":"pone.0285529.ref017","article-title":"Statins for the treatment of dementia.","author":"B McGuinness","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"pone.0285529.ref018","author":"US","year":"2019","journal-title":"Food and Drug safety administration \u201cFDA Drug Safety Communication: Important safety changes to cholesterol\u2013lowering statin drugs."},{"issue":"11","key":"pone.0285529.ref019","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","article-title":"Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults","volume":"117","author":"MF Muldoon","year":"2004","journal-title":"Am J Med"},{"issue":"10263","key":"pone.0285529.ref020","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"B Gencer","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"pone.0285529.ref021","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jacl.2020.05.008","article-title":"Statin use and fall-related hospitalizations among residents of long-term care facilities: A case-control study","volume":"14","author":"K. N. Wang","year":"2020","journal-title":"Journal of Clinical Lipidology"},{"issue":"10","key":"pone.0285529.ref022","doi-asserted-by":"crossref","first-page":"e006364","DOI":"10.1136\/bmjopen-2014-006364","article-title":"NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer\u2019s disease","volume":"4","author":"B Lawlor","year":"2014","journal-title":"BMJ Open"},{"issue":"9","key":"pone.0285529.ref023","doi-asserted-by":"crossref","first-page":"e1002660","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial","volume":"15","author":"B Lawlor","year":"2018","journal-title":"PLoS Med."},{"issue":"1","key":"pone.0285529.ref024","first-page":"33","article-title":"Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data, Age and Ageing","volume":"46","author":"Fiona Clague","year":"2017"},{"issue":"10263","key":"pone.0285529.ref025","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"B Gencer","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"pone.0285529.ref026","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1532-5415.2006.00889.x","article-title":"Polypharmacy and prescribing quality in older people.","volume":"54","author":"MA Steinman","year":"2006","journal-title":"J Am Geriatr Soc."},{"issue":"5","key":"pone.0285529.ref027","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00228-010-0977-0","article-title":"Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study","volume":"67","author":"A Nobili","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"pone.0285529.ref028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000311032","article-title":"Impact of dementia on hospitalization.","volume":"35","author":"R Guijarro","year":"2010","journal-title":"Neuroepidemiology."},{"issue":"2","key":"pone.0285529.ref029","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/gerona\/glw140","article-title":"Impact of Potentially Inappropriate Prescribing on Adverse Drug Events, Health Related Quality of Life and Emergency Hospital Attendance in Older People Attending General Practice: A Prospective Cohort Study","volume":"72","author":"E Wallace","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"pone.0285529.ref030","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.11.002","article-title":"Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study","volume":"21","author":"K Bettermann","year":"2012","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"pone.0285529.ref031","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pharmthera.2016.11.001","article-title":"Intensive LDL-cholesterol lowering therapy and neurocognitive function","volume":"170","author":"M Banach","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"5","key":"pone.0285529.ref032","first-page":"507","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"28","author":"EC Kemp","year":"2020","journal-title":"Statin Use and Risk of Cognitive Decline in the ADNI Cohort. Am J Geriatr Psychiatry."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0285529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T18:52:28Z","timestamp":1702407148000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0285529"}},"subtitle":[],"editor":[{"given":"Mario Ulises","family":"P\u00e9rez-Zepeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0285529","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]}}}